5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Bladder Cancer Therapeutics and Diagnostics Market is Segmented by Cancer Type (Transitional Cell Bladder Cancer, Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer, and Other Rare Types), Therapeutics, Diagnostics, and Geography.
Fastest Growing Market:
The bladder cancer therapeutics and diagnostics market will witness rapid growth due to the increasing awareness about bladder diseases and available therapies, along with growing healthcare expenditure and innovation in drug development. There has been a rapid increase in the overall healthcare expenditure, globally, over the past few years. Therefore, there are new medical technologies, treatments, and medicines available for bladder cancer diseases that contribute majorly to the overall rise in healthcare costs. The high drug prices, drug patent expiry, and cost of healthcare services account for the two-third increase in healthcare spending. The expenditure on increased services, which includes costs of labor and productivity (in biopharmaceutical industries), is also one of the major factors driving healthcare costs.
In addition, the growing research in the development of innovative bladder cancer therapies and the availability of pipeline therapeutics are further propelling the growth of the bladder cancer therapeutics market. Furthermore, the rise in awareness about bladder cancer and its available therapies and the growing smoking and tobacco consumption are also driving the market.
As per the scope of the report, bladder cancer is a tumor that starts in the cells of the bladder. Bladder cancer is the rapid, uncontrolled growth of abnormal cells in the urinary bladder lining with epithelial cells. These cancerous cells may even spread through the lining into the muscular wall of the bladder. Several therapies have been developed to treat bladder cancers, which, in turn, build a high demand for the bladder cancer therapeutics market.
|By Cancer Type|
|Transitional Cell Bladder Cancer|
|Squamous Cell Bladder Cancer|
Report scope can be customized per your requirements. Click here.
Cystoscopy is a procedure used to observe the interiors of the bladder and urethra using a telescope. A cystoscope is a specialized endoscope that is inserted through the urethra into the bladder to allow direct visual inspection of the urothelium. Cystoscopy is thus cost-effective, though, in combination with other tests, its cost can vary. There are approximately 1.2 million flexible cystoscopy procedures conducted annually in the United States, and thus, the introduction of Cysview is boosting the growth of the market and is expected to record a higher growth rate, during the forecast period.
To understand key trends, Download Sample Report
The ecosystem for R&D in drugs, for cancer, is well established in North America, particularly in the United States. Additionally, the presence of a large number of biologics companies and biopharmaceutical companies is contributing to the large size and excellent growth of the bladder cancer therapeutics and diagnostics market.
North America also has the best adoption rates of new diagnostic modalities that are introduced in the commercial space. This trend is in contrast with other regions of the world, where the most widely adopted technologies for cancer diagnostics are at least a decade old. Consequently, North America is a leader in terms of the market size in the bladder therapeutics and diagnostics market.
To understand geography trends, Download Sample Report.
The major companies active in the market are AstraZeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, Epocrates, Genentech, GlaxoSmithKline, Roche, Merck & Co., Novartis, Pfizer, and so on. The companies present in the market are found focusing on product innovations, expansions, finding new markets or innovating their core competency, to expand their market share.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Awareness about Bladder Diseases and Available Therapies
4.2.2 Increasing Healthcare Expenditure
4.2.3 Increasing Prevalence of Bladder Cancer
4.3 Market Restraints
4.3.1 Rise in the Number of Patent Expiration and Increase Use of Generic Drugs
4.3.2 Asymptomatic Nature of the Disease
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Therapeutics
5.2 By Diagnostics
5.2.2 Bladder Ultrasound
5.2.4 Other Diagnostics
5.3 By Cancer Type
5.3.1 Transitional Cell Bladder Cancer
5.3.2 Squamous Cell Bladder Cancer
5.4.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.4.4 Middle East & Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle East & Africa
5.4.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Astra Zeneca PLC
6.1.2 Bristol Myers Squibb
6.1.3 Celgene Corporation
6.1.4 Eli Lilly and Co.
6.1.5 GlaxoSmithKline PLC
6.1.6 F Hoffmann-La Roche AG
6.1.7 Novartis International AG
6.1.8 Pfizer Inc.
6.1.9 Sanofi SA
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments